Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy-Reference-Cited by-同舟云学术

Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy

Published:2011-09-07 Issue:4 Volume:19 Page:413-425
ISSN:1868-6974
Container-title:Journal of Hepato-Biliary-Pancreatic Sciences
language:en
Short-container-title:Journal of Hepato-Biliary-Pancreatic Sciences

Author:

Murata Yasuhiro¹,Hamada Takashi¹,Kishiwada Masashi¹,Ohsawa Ichiro¹,Mizuno Shugo¹,Usui Masanobu¹,Sakurai Hiroyuki¹,Tabata Masami¹,Ii Noriko²,Inoue Hiroyuki³,Shiraishi Taizo⁴,Isaji Shuji¹

Affiliation:

1. Department of Hepatobiliary Pancreatic and Transplant Surgery; Mie University Graduate School of Medicine; 2-174 Edobashi Tsu 514-8507 Japan

2. Department of Radiology; Mie University Graduate School of Medicine; Tsu Japan

3. Department of Gastroenterology and Hepatology; Mie University Graduate School of Medicine; Tsu Japan

4. Department of Pathology; Mie University Graduate School of Medicine; Tsu Japan

Publisher

Wiley

Subject

Hepatology,Surgery

Link

http://www.springerlink.com/index/pdf/10.1007/s00534-011-0440-3

Reference39 articles.

1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol.,1997

2. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial;Regine;JAMA,2008

3. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial;Oettle;JAMA,2007

4. CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC);Neuhaus;J Clin Oncol.,2008

5. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience;Richter;World J Surg.,2003

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients;BMC Gastroenterology;2023-02-08

2. The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors;ACS Pharmacology & Translational Science;2020-11-23

3. “Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer;Cancers;2020-10-31

4. Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis;JCO Precision Oncology;2019-12

5. Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Ductal Adenocarcinoma Patients;Cancers;2019-04-10